Education
About Us
Working with TipRanks
Follow Us
Delcath Systems (DCTH)
NASDAQ:DCTH
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.02Last Year’s EPS
-0.45Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 06, 2025
|% Change Since: -0.22%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance in the U.S. market with the launch of HEPZATO and significant growth in Europe, despite challenges with pricing and high operational expenses. The company's strategic focus on expanding treatment centers and R&D initiatives suggests a positive outlook.Company Guidance
In the fourth quarter of 2024, Delcath Systems reported significant milestones, including $13.7 million in HEPZATO revenue from 14 active U.S. treatment centers and a 137% growth in European sales. The company achieved a gross margin of 86% for the quarter and 83% for the full year, while the cash burn was reduced to $1 million. Notably, Delcath ended the year with $53.2 million in cash and investments and no debt. They activated three new U.S. treatment centers in Q4, with plans to increase to 30 centers by year-end 2025. The company also expanded its commercial team to support this growth, and aims for a positive adjusted EBITDA, having reached $4.6 million in Q4. Key R&D initiatives include expanding HEPZATO's indications, with a Phase 2 trial for metastatic CRC slated for the second half of 2025, targeting a market of 6,000 to 10,000 patients annually.Successful U.S. Launch of HEPZATO
Generated $32.3 million of HEPZATO revenue in the U.S. for 2024, including $13.7 million in Q4 from 14 active U.S. treatment centers.
Positive Financial Performance
Achieved $4.6 million in positive adjusted EBITDA in Q4, a first for the company. Ended the year with $53.2 million in cash and investments with no debt.
European Growth
European revenue growth of 137% over 2023, with Germany up 75% and other markets including the UK and Turkey doubling year-over-year.
Expansion of Treatment Centers
Activated three new U.S. treatment centers in Q4, bringing the total to 16 active centers, with plans to reach 30 centers by year-end 2025.
Strategic R&D Initiatives
Received FDA clearance for a Phase 2 trial in metastatic CRC and planning a Phase 2 trial in metastatic breast cancer.
---
DCTH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DCTH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 06, 2025 | $13.43 | $13.22 | -1.56% |
| Nov 08, 2024 | $10.94 | $11.06 | +1.10% |
| Aug 05, 2024 | $8.32 | $7.91 | -4.93% |
| May 14, 2024 | $5.40 | $7.07 | +30.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Delcath Systems (DCTH) report earnings?
Delcath Systems (DCTH) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Delcath Systems (DCTH) earnings time?
Delcath Systems (DCTH) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DCTH EPS forecast?
DCTH EPS forecast for the fiscal quarter 2025 (Q1) is 0.02.
---